AKT1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, a significant main effect for treatment (F (1, 18) = 6.1, p = 0.02) and group (i.e., CON, NAFLD, ESLD) (F (2, 18) = 4.1, p = 0.04) was identified for the phosphorylation of Akt.